NCT01540071View on ClinicalTrials.gov

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Castration Resistant Prostate Cancer

Interventions

DRUG

NRX 194204

NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day

Trial Locations (1)

92708

Lalita Pandit, MD, Fountain Valley

Sponsors

Lead Sponsor

Io Therapeutics

All Listed Sponsors

lead

Io Therapeutics

INDUSTRY